Fox Chase’s Dr. Daniel Geynisman Named Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network

Dr geynisman
Daniel M. Geynisman, Chief of the Division of Genitourinary Medical Oncology, has been appointed Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network.

PHILADELPHIA (May 16, 2024) — Daniel M. Geynisman, MD, Chief of the Division of Genitourinary Medical Oncology and an Associate Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has been appointed Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network. The National Comprehensive Cancer Network (NCCN) is a nonprofit alliance of leading cancer centers devoted to patient care, research, and education.

“It is an honor to be named Editor-in-Chief for JNCCN,” said Geynisman. “Fox Chase Cancer Center was a founding member institution for NCCN, and the opportunity to lead JNCCN is an enormous privilege. I am excited to expand upon the legacy of practice-setting guidelines and outstanding research contributions published in JNCCN and look forward to working with the editorial board and journal staff to continue to build and grow the journal as a premier destination for oncology research.” 

JNCCN is dedicated to improving the quality of cancer care locally, nationally, and globally, and is focused on the highest quality original research in the areas of outcomes, quality improvement, and policy. It is also a trusted resource for information on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). 

“We are thrilled to welcome Dr. Geynisman into this crucial position for JNCCN,” said Crystal S. Denlinger, MD, Chief Executive Officer for NCCN. “Our journal fills many important roles when it comes to oncology knowledge sharing. In addition to publishing exclusive insights and updates for the NCCN Guidelines, JNCCN publishes rigorous health services research, original investigations, and reviews addressing all aspects of cancer care delivery. Its impact factor grows every year — currently calculated at 13.4, placing it in the top 10% of cancer-related publications. We look forward to seeing what new heights we can reach under Dr. Geynisman’s leadership.” 

Geynisman has served as medical oncology section editor for Urologic Oncology: Seminars and Original Investigations since 2018 and has authored more than 130 peer-reviewed publications. He also has a long history of advancing cancer care with NCCN, including serving as a member on the NCCN Guidelines Panels for both Testicular Cancer and Wilms Tumor. 

He has reviewed abstracts for presentation at the NCCN Annual Conference, served on various NCCN grant selection committees, and was himself a past recipient of NCCN research grants through NCCN’s Oncology Research Program. He also serves as an ad hoc reviewer for multiple other journals, including the New England Journal of Medicine, European Urology, Journal of Clinical Oncology, and Cancer

Geynisman earned his medical degree from the University of Pittsburgh School of Medicine and completed a residency in internal medicine at the University of Pittsburgh Medical Center, where he served an additional year as chief resident. He then completed a hematology/oncology fellowship at the University of Chicago Medical Center, where he served as chief fellow in his final year. While there, he completed an additional fellowship at the MacLean Center for Clinical Medical Ethics. He specializes in treating patients with genitourinary cancers, including prostate, bladder, kidney, testicular, penile, and adrenal cancers. 

Geynisman’s first issue as Editor-in-Chief will be published in June.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427